Objective: To elucidate the chemosensitivity of retinoic acid (RA)-differentiated medulloblastoma Med-3 cells to conventional anti-cancer drug and to determine the potential genetic factor(s) mediating this sensitivity.
Methods: Ten mumol/L RA, 5 micrograms/ml cisplatin (DDP) and their combination with one half concentration of each were used respectively to treat human medulloblastoma cell line Med-3 in vitro. Cell proliferation, morphology and death pattern as well as Fas/FasL expressions were analyzed by multiple approaches.
Results: Both soluble and membrane FasL could be detected in the treated and untreated Med-3. Fas was positive in the cytoplasm of Med-3 cells and the cells could produce soluble Fas. DDP had no obvious effect on Fas expression. RA up-regulated Fas expression and translocalization from cytoplasm to cell membrane of the treated cells. Neither RA nor DDP could trigger apoptosis but in combination could effectively induce apoptosis.
Conclusion: RA could enhance the apoptotic susceptibility of Med-3 cells to DDP presumably through modulating the Fas expression pattern. Combined RA/DDP regimen would have potential clinical value in the management of medulloblastomas.